User:H2OBear/sandbox

An extracellular vesicle (EV) is a lipid bilayer-delimited particle that is naturally released from a cell and cannot replicate. EVs range in diameter from near the size of the smallest physically possible unilamellar liposome (around 20-30 nm) to as large as 10 microns or more. They carry a cargo of proteins, nucleic acids, metabolites, and even organelles from the parent cell. Most cells that have been studied to date are thought to release EVs, including some bacterial, fungal, and plant cells that are surrounded by cell walls. A wide variety of EV subtypes have been proposed, defined variously by size, biogenesis pathway, cargo, cellular source, and function.

Numerous functions of EVs have been established or postulated. The first evidence for the existence of EVs was enabled by the ultracentrifuge, the electron microscope, and functional studies of coagulation in the mid-20th century. A sharp increase in interest in EVs occurred in the first decade of the 20th century following the discovery that EVs could transfer nucleic acids from cell to cell. Associated with EVs from certain cells or tissues, nucleic acids could be easily amplified as markers of disease and also potentially traced back to a cell of origin, such as a tumor cell. The discovery also implied that EVs could be used for therapeutic purposes, such as delivering nucleic acids or other cargo to diseased tissue. This growing interest was paralleled by formation of companies and funding programs focused on development of EVs as biomarkers or therapies of disease, the founding of an International Society for Extracellular Vesicles (ISEV), and establishment of a scientific journal devoted to the field, the Journal of Extracellular Vesicles.

Background/History
Evidence for the existence of EVs and their functions was first gathered by combined applications of ultracentrifugation, electron microscopy, and functional studies during the mid-20th century. Ultracentrifuged pellets from blood plasma were reported to have procoagulant properties by Erwin Chargaff and Randolph West in 1946. The platelet derivation and lipid-containing nature of these particles was further articulated by Peter Wolf. Around the same time, H. Clarke Anderson and Ermanno Bonucci separately described the calcifying properties of EVs in bone matrix.

Although the extracellular and vesicular properties of EVs had been recognized by numerous groups by the 1970s, the term “extracellular vesicle” was first used in a manuscript title in 1971. This electron microscopy study of the flagellate freshwater alga Ochromonas danica reported release of EVs from membranes including those of flagella. Soon thereafter, EVs were seen to be released from follicular thyroid cells of the bat during arousal from hibernation, suggesting the possible involvement of EVs in endocrine processes. Reports of EVs in intestinal villi samples and, for the first time, in material from human cancer (adenoma) referred back to even earlier publications that furnished similar evidence, although conclusions about EV release had not then been drawn. EVs were also described in bovine serum and cell culture conditioned medium with distinctions made between “vesicles of the multivesicular body” and “microvesicles.” These studies further noted the similarities of EVs and enveloped viruses.

In the early- to mid-1980s, the Stahl and Johnstone labs forged a deeper understanding of the release of EVs from reticulocytes , while progress was also made on EVs shed from tumor cells. The reticulocyte research, in particular, showed that EVs could be released not only from the plasma membrane, but also by fusion of the multivesicular body with the plasma membrane. During this time, EVs were described by many names, sometimes in the same manuscript, such as “shedding vesicles,” “membrane fragments,” “plasma membrane vesicles,” “micro-vesicles/microvesicles,” “exosomes,” (previously used for mobile, transforming DNA elements in model organisms like Drosophila and Neurospora ), “inclusion vesicles,” and more, or referred to by organ of origin, such as “prostasomes” that were found to enhance sperm motility in semen.

The involvement of EVs in immune responses became increasingly clear in the 1990s with findings of the group of Graça Raposo and others. A clinical trial of dendritic cell-derived EVs was performed in France just before the turn of the century (add detailles). Cells of the immune system were found capable of transferring transmembrane proteins via EVs. For example, the HIV co-receptors CCR5 and CXCR4 could be transferred from an HIV-susceptible cell to a refractory cell by "microparticles," rendering the recipient cell permissive to infection.

Beginning in 2006, several laboratories reported that EVs contain nucleic acids and have the ability to transfer them from cell to cell. Some RNAs were even found to be function in the recipient cell. Whether carrying RNA, surface molecules, or other factors, the involvement of EVs in cancer progression aroused considerable interest, leading to hypotheses that specific EVs could target specific cells due to "codes" displayed on their surface; create or enhance a metastatic niche; betray the presence of specific cancers; or be used as a therapy to target cancer cells. Meanwhile, strides were made in the understanding of vesicle biogenesis and subtypes.

Rapid growth of the EV research community in the early 2000s led to the creation of the International Society for Extracellular Vesicles (ISEV), which has led efforts for rigor and standardization in the field including establishment of the Journal of Extracellular Vesicles. A plethora of national and regional EV societies have also been formed. In 2012, the Director’s Office of the US National Institutes of Health (NIH) announced a program for funding of EV and extracellular RNA studies, the Extracellular RNA Communication Consortium (ERCC), which subsequently invested >USD 100 million in EV research. A second round of funding was announced in 2018. Commercial investment in EV diagnostics and therapeutics also grew during this time. Exosome Diagnostics has developed several cancer diagnostic assays based in part on EV RNA. Codiak Biosciences is a company with intellectual property in the pancreatic cancer space.

Biogenesis and nomenclature
Diverse EV subtypes have been proposed, with names such as ectosomes, microvesicles, microparticles, exosomes, oncosomes, apoptotic bodies, and more. These EV subtypes have been defined by various, often overlapping, definitions, based mostly on biogenesis (cell pathway, cell or tissue identity, condition of origin). However, EV subtypes may also be defined by size, constituent molecules, function, or method of separation. Because of the bewildering and sometimes contradictory definitions of different EV subtypes, the current scientific consensus is that “extracellular vesicle” and variations thereon are the preferred nomenclature unless specific biogenetic origin can be demonstrated. Subtypes of EVs may be defined by: ""a) physical characteristics of EVs, such as size (“small EVs” (sEVs) and “medium/large EVs” (m/lEVs), with ranges defined, for instance, respectively, <100nm or <200nm [small], or >200nm [large and/or medium]) or density (low, middle, high, with each range defined); b) biochemical composition (CD63+/CD81+- EVs, Annexin A5-stained EVs, etc.); or c) descriptions of conditions or cell of origin (podocyte EVs, hypoxic EVs, large oncosomes, apoptotic bodies)."

Ectosome/microvesicle/microparticle (plasma membrane origin)
The terms “ectosome,” “microvesicle” (MV), and “microparticle” (MP) refer to particles released from the surface of cells. Especially in the field of platelet research, MP has been the standard nomenclature. Formation of ectosomes may in some cases result from directed processes, and in others from shear forces or adherence of the PM to a surface.

Exosome (endosomal origin)
Exosome biogenesis begins with pinching off of endosomal invaginations into the multivesicular body (MVB), forming intraluminal vesicles (ILVs). If the MVB fuses with the plasma membrane, the ILVs are released as “exosomes.” It should be noted that the first publication to use the term “exosome” for EVs presented it as a synonym for “micro-vesicle.” TRAMS The term has also been used for EVs within specific size ranges, EVs separated with specific methods, or even all EVs. Please see the article on exosomes for more details on exosome biogenesis.

Apoptotic body
Apoptotic bodies are EVs that are released by dying cells undergoing apopotosis. Since apoptotic cells tend to display phosphatidylserine (PS) in the outer bilayer of the cell membrane, apoptotic bodies tend to externalize PS, although other EVs may also do so. Apoptotic bodies may be quite large (microns in diameter) but may also measure in the submicron range.

Large oncosomes, exophers, and other very large EVs
In addition to the very large EVs released during apoptosis, micron-sized EVs may be produced by cancer cells, neurons, and other cells. When produced by cancer cells, these particles are termed “large oncosomes” and may reach 20 microns or more in diameter. These large EVs are practically cells except without full nuclei. They contain a functional cytoskeleton and energy sources (mitochondria), and may be motile, contributing to metastasis. Another class of large EV has been observed in neurons of the model organism C. elegans. When injected with a dye, neurons were observed to sequester the dye into a portion of the cell and release it in a large EV dubbed the “exopher.” This body was hypothesized to be a mechanism for disposal of unwanted cellular material. Technically, the platelets of certain vertebrates (which bud from megakaryocytes), as well as red blood cells (e.g., of adult humans) also fulfill the consensus definition of EVs.

Enveloped virus
Enveloped viruses are a type of EV produced under the influence of viral infection. That is, the virion is composed of cellular membranes but contains proteins and nucleic acids produced from the viral genome. Some enveloped viruses can infect other cells even without a functional virion, when genomic material is transferred via EVs. Certain non-enveloped viruses may also reproduce with assistance from EVs.

Exomere
The “exomere” is a recently discovered particle type that may be related to EVs. in the size range of small EVs (as separated by asymmetric flow field-flow fractionation), the relationship of exomeres to EVs remains to be elucidated.

EV separation and concentration
Studying EVs and their cargo typically requires separation from a biological matrix (such as a complex fluid or tissue) so that the uniquely EV components can be analyzed. Many approaches have been used, including differential ultracentrifugation, density gradient ultracentrifugation, size exclusion chromatography, ultrafiltration, and affinity/immunoaffinity capture methods. Each method has its own recovery and purity outcomes: that is, what percentage of input EVs are obtained, and the ratio of “true” EV components to co-isolates. EV separation can also be influenced by pre-analytical variables.

Population-level EV analysis
Separated or concentrated populations of EVs may be characterized by several means. Total concentration of molecules in categories such as protein, lipid or nucleic acid. Total particle counts in a preparation can also be estimated, for example by light-scattering techniques. It should be noted, however, that each measurement technology may have a specific size range for accurate quantitation, and that very small EVs (<100 nm diameter) are not detected by many technologies. Molecular “fingerprints” of populations can be obtained by “omics” technologies like proteomics, lipidomics, and RNomics, or by techniques like Raman spectroscopy. Overall levels of unique molecules can also be measured in the population, such as tetraspanins, phosphatidylserine, or species of RNA. It has been proposed that purity of an EV preparation can be estimated by examining the ratio of one population-level measurement to another, e.g., the ratio of total protein or total lipid to total particles.

Single-particle analysis
Specialized methods are needed to study EVs at the single particle level. The challenge for any putative single-particle method is to identify the individual EV as a single, lipid-bilayer particle, and to provide additional information such as size, surface proteins, or nucleic acid content. Methods that have been used successfully for single-EV analysis include optical microscopy and flow cytometry (for large EVs, usually >200 nm), electron microscopy (no lower bound), single-particle interferometric reflectance imaging (down to about 40 nm), and nano-flow cytometry (also to 40 nm). Some technologies allow the study of individual EVs without extensive prior separation from a biological matrix: to give a few examples, electron microscopy and flow cytometry.

Enriched and depleted markers
To demonstrate the presence of EVs in a preparation, as well as the relative depletion of non-EV particles or molecules, EV-enriched 'and' -depleted markers are necessary: For example, the MISEV2018 guidelines recommend:
 * At least one membrane-associated marker as evidence of the lipid bilayer (e.g., a tetraspanin protein)
 * At least one cytoplasmic but ideally membrane-associated marker to show that the particle is not merely a membrane fragment
 * At least one “negative” or “depleted” marker: a “deep cellular” marker, a marker of a non-EV particle, or a soluble molecule not thought to be associated with EVs.

Usually, but not necessarily, the EV-enriched or -depleted markers are proteins that can be detected by Western blot, ELISA, mass spectrometry, or other widely-available methods. Assaying for depleted markers is thought to be particularly important, as otherwise the purity of an EV preparation cannot be claimed. However, most studies of EVs prior to 2016 did not support claims of the presence of EVs by showing enriched markers, and <5% measured the presence of possible co-isolates/contaminants.

Biological functions of EVs
A wide variety of biological functions have been ascribed to EVs.


 * “Trash disposal”: eliminating unwanted materials
 * Transfer of functional proteins
 * Transfer of functional RNA
 * Molecular recycling or “nutrition”
 * Signaling to the recipient cell via cell-surface or endosomal receptors
 * Creation of a metastatic niche for cancer
 * Pathfinding through the environment
 * Quorum sensing
 * Mediating host-commensal or parasite/pathogen interaction